Allopurinol-thiopurine combination therapy in inflammatory bowel disease: Are there genetic clues to this puzzle?

Pharmacogenomics

Volumn 11, Issue 11, 2010, Pages 1505-1508

  Roberts, Rebecca L ^a,b   Gearry, Richard B ^b,c   Barclay, Murray L ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

6 mercaptopurine; 6 TGN; aldehyde oxidase; azathioprine; GMPS; IMPDH; preferential 6 MMP metabolism; thiopurine S methyltransferase; xanthine oxidase inhibitor

Indexed keywords

6 METHYLTHIOINOSINE; ALLOPURINOL; GUANOSINE PHOSPHATE; INOSINATE DEHYDROGENASE; MERCAPTOPURINE; RAC1 PROTEIN; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE;

ANTIINFLAMMATORY ACTIVITY; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG METABOLISM; EDITORIAL; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

6-MERCAPTOPURINE; ALLOPURINOL; AZATHIOPRINE; BIOTRANSFORMATION; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; HUMANS; INFLAMMATORY BOWEL DISEASES; POLYMORPHISM, GENETIC; XANTHINE OXIDASE;

EID: 78649715357     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.143     Document Type: Editorial

References (22)

1. Pearson, DC, May GR, Fick G et al.: Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. 2, CD000067, (2000).
2. Timmer A, McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 1, CD000478 (2007).
3. + T lymphocytes. J. Clin. Invest. 111, 1133-1145 (2003).
4. Cuffari C, Theoret Y, Latour S et al.: 6-mercaptopurine metabolism in Crohn's disease: correlation with effcacy and toxicity. Gut 39, 401-406 (1996).
5. Dubinsky MC, Hassard PV, Seidman EG et al.: An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Infamm. Bowel Dis. 7, 181-189 (2001).
6. Dubinsky MC, Lamothe S, Yang HY et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in infammatory bowel disease. Gastroenterology 118, 705-713 (2000).
7. Gardiner SJ, Gearry RB, Burt MJ et al.: Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur. J. Gastroenterol. Hepatol. 20, 1238-1242 (2008).
8. Chocair P, Duley J, Simmonds HA et al.: Low-dose allopurinol plus azathioprine/ cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 342, 83-84 (1993).
9. Sparrow MP, Hande SA, Friedman S et al.: Allopurinol safely and effectively optimizes tioguanine metabolites in infammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 22, 441-446 (2005).
10. Sparrow MP, Hande SA, Friedman S et al.: Effect of allopurinol on clinical outcomes in infammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 5, 209-214 (2007).
11. Witte TN, Ginsberg AL: Use of allopurinol with low-dose 6-mercaptopurine in infammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can. J. Gastroenterol. 22, 181-185 (2008).
12. Rahhal RM, Bishop WP: Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric infammatory bowel disease. Infamm. Bowel Dis. 14, 1678-1682 (2008).
13. Ansari A, Elliott T, Baburajan B et al.: Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating infammatory bowel disease. Aliment. Pharmacol. Ther. 28, 734-741 (2008).
14. Gardiner SJ, Gearry RB, Burt MJ et al.: Allopurinol may improve response to azathioprine and 6-mercaptopurine by correcting an unfavourable metabolite ratio. J. Gastroenterol. Hepatol. DOI:10.1111/j.1440-1746.2010.06489.x (2010) (Epub ahead of print).
15. Duley JA, Chocair PR, Florin TH: Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment. Pharmacol. Ther. 22, 1161-1162 (2005).
16. Roberts RL, Gearry RB, Kennedy MA et al.: Beyond TPMT: genetic infuences on thiopurine drug responses in infammatory bowel disease. Per. Med. 5, 233-248 (2008).
17. Roberts RL, Gearry RB, Bland ML et al.: Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet. Genomics 18(5), 434-438 (2008).
18. Spire-Vayron de la Moureyre C, Debuysere H, Fazio F et al.: Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9, 189-198 (1999).
19. Roberts RL, Gearry RB, Barclay ML et al.: IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J. 7, 312-317 (2007).
20. Wong DR, Derijks LJ, den Dulk MO et al.: The role of xanthine oxidase in thiopurine metabolism: a case report. Ther. Drug Monit. 29, 845-848 (2007).
21. Kudo M, Moteki T, Sasaki T et al.: Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet. Genomics 18, 243-251 (2008).
22. Smith MA, Marinaki AM, Arenas M et al.: Novel pharmacogenetic markers for treatment outcome in azathioprine-treated infammatory bowel disease. Aliment. Pharmacol. Ther. 30, 375-384 (2009).